Thymosin β4 fragment analog
TB-500
Cited range Sparse human data
What it is
TB-500 is a synthetic peptide associated with the active region of thymosin beta-4, a 43-amino-acid protein involved in actin sequestration and cell motility. Research-chemical products labeled TB-500 are not the same as pharmaceutical-grade Tβ4 used in some clinical programs.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- This is the short stand-in for thymosin β4, a protein your body already uses to move cells during repair.
- The pitch is flexibility and recovery: help cells migrate into damaged muscle, tendon, or heart tissue.
- Animal work also touches blood-vessel growth and inflammation calm-down after injury.
- People use it when they want a more “whole-body recovery” partner next to BPC-157.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Tβ4 binds G-actin, influences cytoskeletal remodeling, cell migration, and has been studied for angiogenesis and reduced fibrosis after injury. TB-500 is sold as a shorter, more practical analog of that biology. Confirming that a given vial matches the intended sequence requires a COA, not a label claim.
Possible side effects / caveats
Human safety for gray-market TB-500 is poorly characterized. Expected issues if misused: injection-site reactions, unknown systemic effects, and theoretical concerns around unregulated angiogenesis. Do not conflate Tβ4 trial data with untested research vials.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 2–5 mg per administration | 2×/week for a loading stretch, then weekly | Most common secondary-source pattern |
| Cited range | ~4–8 weeks loading then taper | Cycled | Not a validated clinical schedule |